NeurAxis Closes $5 Million Direct Stock Offering
NeurAxis, Inc. (NYSE American: NRXS), a leader in medical technology focused on innovative neuromodulation therapies, has successfully closed a direct registered offering of 1,538,461 common stock shares priced at $3.25 each. This strategic move has successfully generated gross proceeds of approximately $5 million, enhancing the company’s financial stability and positioning for future growth.
Significance of the Funding
Brian Carrico, NeurAxis’s President and CEO, expressed that this financing milestone, in conjunction with the recent FDA clearance for IB-Stim to treat Pediatric Functional Abdominal Pain (FAP), is critical for the company's future. The $5.0 million influx of capital, along with over $1 million raised through warrant exercises, significantly bolsters their balance sheet as they head into the next stages of revenue generation for IB-Stim. Notably, the upcoming implementation of their CPT Category I code, effective on January 1, 2026, is aimed at expanding access to their treatments, which is especially important considering the scarcity of FDA-approved medications for pediatric abdominal pain disorders linked to gut-brain interactions.
The Role of Craig-Hallum Capital Group
Craig-Hallum Capital Group played a crucial role as the exclusive placement agent during this offering. Their expertise in market dynamics and investor relations has been instrumental for NeurAxis in achieving this successful capital raise.
Future Steps and Clinical Trials
The funds raised will enable NeurAxis to upscale its operations and continue its commitment to the advancement of neuromodulation therapies for chronic conditions. Their flagship product, IB-Stim™, utilizes innovative Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which has already received FDA clearance for additional treatments. Furthermore, ongoing clinical trials are assessing the efficacy of PENFS in both pediatric and adult patient populations, aiming to address significant unmet healthcare needs.
About NeurAxis, Inc.
NeurAxis, Inc. is dedicated to providing cutting-edge neuromodulation therapies aimed at improving the quality of life for individuals with debilitating chronic conditions. Their commitment to scientific advancement and evidence-based medicine drives the adoption of their proprietary therapies, which provide new options for patients suffering from various health challenges.
Frequently Asked Questions
What amount did NeurAxis raise in this stock offering?
NeurAxis raised approximately $5 million from its recent direct stock offering.
Who acted as the placement agent for NeurAxis’s offering?
Craig-Hallum Capital Group served as the exclusive placement agent for this offering.
What is the significance of FDA clearance for NeurAxis?
The FDA's clearance for IB-Stim treatments marks a pivotal advancement for NeurAxis, allowing them to provide necessary therapies for pediatric patients dealing with abdominal pain.
What is IB-Stim technology?
IB-Stim™ is NeurAxis's exclusive Percutaneous Electrical Nerve Field Stimulation (PENFS) technology designed to treat functional abdominal pain, particularly in children and adolescents.
What future developments can we expect from NeurAxis?
NeurAxis plans to use the funds to continue expanding its product offerings and conducting additional clinical trials to validate the efficacy of its technologies in various conditions.
